Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy.

abstract：:Interleukin-12 (IL-12) has important immunomodulatory effects on T and natural killer (NK) cells that might be exploited in anticancer treatment. Murine IL-12 models have shown antimetastatic and antitumor effects against murine tumors in vivo. Data on the effects of human IL-12 on human tumors are confined to 51Cr-re...

journal_title：Anti-cancer drugs

authors： Izquierdo MA,Degen D,Sypek JP,Von Hoff DD

更新日期：1996-05-01 00:00:00

abstract：:In the present study we investigated the enhancement of cytotoxicity of peritoneal macrophages induced by OK-432. Rats received an i.p. injection of OK-432 at doses of 0.1, 0.5 or 1.0 KE/rat. Two days later, rats were sacrificed and peritoneal macrophages were isolated. Then the number of macrophages was counted, and ...

journal_title：Anti-cancer drugs

authors： Huang Y,Xu Y,Yamagishi H,Hagiwara A

更新日期：2001-10-01 00:00:00

abstract：:The use of viability assays to assess the effect of antineoplastic agents on cell lines and tumor cells is an important investigative tool and may have clinical relevance. Such assays require very small quantities of drugs and it is the practice of many laboratories to freeze aliquots of drugs for use in these assays ...

journal_title：Anti-cancer drugs

authors： Hunter EM,Sutherland LA,Cree IA,Subedi AM,Hartmann D,Linder D,Andreotti PE

更新日期：1994-04-01 00:00:00

abstract：:Renal cell carcinoma (RCC) is one of the most frequent malignancies of the adults. Its incidence has been increasing steadily by 2-4% each year. Up to 30% of patients present with metastases at diagnosis. It is a highly vascularized cancer because of the hypoxia-induced factor stabilization as a consequence of von Hip...

journal_title：Anti-cancer drugs

authors： Nigro O,Pastore A,Tartaro T,Bolzacchini E,Tuzi A,Pinotti G

更新日期：2019-04-01 00:00:00

abstract：:The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by many tumors, and mediates growth, motility and protection from apoptosis. Inhibition of IGF1R expression or function has been shown to block tumor growth and metastasis, and enhance sensitivity to cytotoxic drugs and irradiation. Thus the IGF1R...

journal_title：Anti-cancer drugs

authors： Bohula EA,Playford MP,Macaulay VM

更新日期：2003-10-01 00:00:00

abstract：:Trichostatin A and helixor A increased thrombospondin-1 expression by ECV304 cells at both mRNA and protein levels by transcriptional activation through the enhancement of tsp-1 promoter activity. The induction of thrombospondin-1 by these agents potently reduced ECV 304 cell migration and capillary-like tube formatio...

journal_title：Anti-cancer drugs

authors： Hong S,Chang SY,Yeom DH,Kang JH,Hong KJ

更新日期：2007-10-01 00:00:00

abstract：:The delivery formulation 5-FU-MS [5-fluorouracil (5-FU) incorporated in microspheres composed of a poly(glycolide-co-lactide) matrix] slowly releases 5-FU over 3 weeks. 5-FU-MS delivers higher concentrations of the drug to the i.p. tissues for a longer period of time with lower blood plasma concentrations than does an...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Shirasu M,Yamasaki J,Togawa T,Takahashi T,Muranishi S,Hyon S,Ikada Y

更新日期：1998-03-01 00:00:00

abstract：:Mantle cell lymphoma (MCL) remains incurable for most patients, and proteasome inhibitors like bortezomib induce responses in a minority of patients with relapsed disease. Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas. We hypothesized that these agents could yield augmented antitumo...

journal_title：Anti-cancer drugs

authors： Cowan AJ,Frayo SL,Press OW,Palanca-Wessels MC,Pagel JM,Green DJ,Gopal AK

更新日期：2015-10-01 00:00:00

abstract：:Creatine kinase (CK), a key enzyme of cellular energetics, has been implicated in tumorigenesis. Cyclocreatine (CCr), which forms a stable phosphagen with a reduced rate of ATP regeneration through CK, inhibits the growth of many solid tumors. We report that CCr induces the formation of unusually stable microtubules t...

journal_title：Anti-cancer drugs

authors： Martin KJ,Vassallo CD,Teicher BA,Kaddurah-Daouk R

更新日期：1995-06-01 00:00:00

abstract：:Long noncoding RNA (lncRNA) KTN1 antisense RNA 1 (KTN1-AS1) is a novel promoter in the progression of some cancers. However, the knowledge of its role in lung adenocarcinoma is still limited. The current study aimed to examine the biological functions of KTN1-AS1 and its coexpressed protein in lung adenocarcinoma. The...

journal_title：Anti-cancer drugs

authors： Li YY,Li W,Chang GZ,Li YM

更新日期：2021-01-22 00:00:00

abstract：:A lack of cross-resistance between the aromatase inhibitors (AIs) provides evidence to suggest that there are clinical differences between these agents. Available data from clinical trials indicate that patients exposed to nonsteroidal AIs may benefit from a steroidal compound of similar biochemical potency, and durab...

journal_title：Anti-cancer drugs

authors： Lønning PE

更新日期：2008-03-01 00:00:00

abstract：:Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cel...

journal_title：Anti-cancer drugs

authors： Boehrer S,Schroeder P,Mueller T,Atz J,Chow KU

更新日期：2011-07-01 00:00:00

abstract：:The clinical development of combinations of cisplatin or carboplatin with DNA topoisomerase I (Topo I) inhibitors is based on their overlapping spectrum of antitumor activity and their in vitro synergy, but is limited by significant hematotoxicity. We studied the cellular interactions between oxaliplatin and topotecan...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Bozec L,Zeghari-Squalli N,Misset JL

更新日期：1999-02-01 00:00:00

abstract：:The tolerance to adriamycin of cancer as a common and stubborn obstacle occurred during curing breast cancer patients needs to be overcome. In the present study, we explored whether inhibiting the glucose transporter 1 (GLUT1) could restore the activity of adriamycin in breast cancer cell line MCF-7 resistant to adria...

journal_title：Anti-cancer drugs

authors： Chen Q,Meng YQ,Xu XF,Gu J

更新日期：2017-09-01 00:00:00

abstract：:Our previous studies have demonstrated the in-vitro and in-vivo targeting of a generation-5 (G5) dendrimer-based multifunctional conjugate, which used folic acid (FA) as the targeting agent and methotrexate (MTX) as the chemotherapeutic drug. For the synthesized G5-FA-MTX nanodevice conjugate to be clinically applicab...

journal_title：Anti-cancer drugs

authors： Myc A,Douce TB,Ahuja N,Kotlyar A,Kukowska-Latallo J,Thomas TP,Baker JR Jr

更新日期：2008-02-01 00:00:00

abstract：:The antitumor effects of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on the human hepatocellular carcinoma SK-HEP-1 cell line have been investigated. The growth of these cultured hepatocellular carcinoma cells was inhibited by MGBCP in a dose-dependent manner. Sper...

journal_title：Anti-cancer drugs

authors： Hashimoto Y,Hibasami H,Tamaki S,Kamei A,Ikoma J,Kaito M,Imoto I,Watanabe S,Nakashima K,Adachi Y

更新日期：1999-03-01 00:00:00

abstract：:Paclitaxel and docetaxel are excellent agents with a high antitumor effect for the treatment of previously anthracycline-exposed metastatic breast cancer. There has been no standard treatment for patients who undergo therapy of a taxan-resistant metastatic breast cancer. Paclitaxel has partial non-cross-resistance in ...

journal_title：Anti-cancer drugs

authors： Suzuma T,Sakurai T,Yoshimura G,Umemura T,Tamaki T,Naito Y

更新日期：2000-08-01 00:00:00

abstract：:We have synthesized and characterized doxorubicin (DOX)-loaded galactosylated gelatin nanovectors using in vitro and in vivo for targeting liver cells including hepatocarcinoma cells. Galactosylated and nongalactosylated gelatin nanovectors (GL-GN-DOX and GN-DOX) were spherical in shape and had mean sizes of about 95....

journal_title：Anti-cancer drugs

authors： Garg M,Madan J,Pandey RS,Sardana S,Katyal A,Chandra R

更新日期：2012-09-01 00:00:00

abstract：:Leucine-rich repeat containing G protein-coupled receptor 5 (Lgr5) is a colorectal cancer (CRC) stem cell marker. The role of Lgr5-expressing stem cells in resistance to chemotherapy is controversial. The notion that Lgr5-expressing cells are more chemotherapy resistant is supported by some data; other data do not sup...

journal_title：Anti-cancer drugs

authors： Planutis AK,Holcombe RF,Planoutene MV,Planoutis KS

更新日期：2015-10-01 00:00:00

abstract：:Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. Th...

journal_title：Anti-cancer drugs

authors： Olbert PJ,Hegele A,Kraeuter P,Heidenreich A,Hofmann R,Schrader AJ

更新日期：2006-09-01 00:00:00

abstract：:Gallbladder carcinoma is the most common malignancy of the biliary tract and is associated with a very poor outcome. The aim of the present study was to investigate the effects of oxymatrine (OM) on gallbladder cancer cells and the possible mechanism of its effects. The effects of OM on the proliferation of gallbladde...

journal_title：Anti-cancer drugs

authors： Wu XS,Yang T,Gu J,Li ML,Wu WG,Weng H,Ding Q,Mu JS,Bao RF,Shu YJ,Cao Y,Wang XA,Ding QC,Dong P,Xie SF,Liu YB

更新日期：2014-10-01 00:00:00

abstract：:We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

journal_title：Anti-cancer drugs

authors： Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

更新日期：1999-07-01 00:00:00

abstract：:Caffeic acid phenethyl ester (CAPE) is a major propolis component that possesses a variety of pharmacological properties such as antioxidant and anticancer effects. Herein, we investigated the effectiveness of CAPE on cytotoxicity of clinically used anticancer drugs, doxorubicin (DXR) and cisplatin (CDDP), in parental...

journal_title：Anti-cancer drugs

authors： Matsunaga T,Tsuchimura S,Azuma N,Endo S,Ichihara K,Ikari A

更新日期：2019-03-01 00:00:00

abstract：:Gefitinib (an epidermal growth factor receptor tyrosine kinase inhibitor) and bexarotene (a rexinoid) affect similar oncogenic pathways and are both metabolized through cytochrome P450 CYP3A4. We studied the combination of bexarotene and gefitinib in the third-line treatment of advanced non-small-cell lung cancer to e...

journal_title：Anti-cancer drugs

authors： Padda SK,Chhatwani L,Zhou L,Jacobs CD,Lopez-Anaya A,Wakelee HA

更新日期：2013-08-01 00:00:00

abstract：:Viscum album L. (mistletoe) extracts are widely used in adjuvant cancer therapy. In contrast to purified components, such as mistletoe lectins and viscotoxins, whole plant extracts of mistletoe resulted in DNA stabilizations in cyclophosphamide-treated lymphocytes but also provided cytotoxicity in tumour cells and lym...

journal_title：Anti-cancer drugs

authors： Büssing A,Suzart K,Schweizer K

更新日期：1997-04-01 00:00:00

abstract：:Response rates reported in early phase II clinical trials are often not reproduced in subsequent larger or phase III studies. Independent review of claimed partial or complete responders to gemcitabine was undertaken in four pivotal, open-label phase II studies of advanced, non-small cell lung cancer (NSCLC) to provid...

journal_title：Anti-cancer drugs

authors： Gwyther SJ,Aapro MS,Hatty SR,Postmus PE,Smith IE

更新日期：1999-09-01 00:00:00

abstract：:In the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G), pertuzumab added to trastuzumab and chemotherapy significantly improved invasive disease-free survival as adjuvant treatment for patients with HER2-positive early breast cancer. The objective of this analysis was to assess the pharmacokinetics of pertuzum...

journal_title：Anti-cancer drugs

authors： Luo Y,Li W,Jiang Z,Zhang Q,Wang L,Mao Y,Tjan-Heijnen VCG,Im SA,McConnell R,Bejarano S,Fumagalli D,Bines J,Wang B,Garg A,Kirschbrown WP,Xu B

更新日期：2019-09-01 00:00:00

abstract：:Dihydroartemisinin (DHA), a semisynthetic derivative of artemisinin, has recently shown antitumor activity in various cancer cells. Its effect on pancreatic cancer is, however, unknown and the mechanism is unclear. The study aims to investigate its antitumor activity and underlying mechanisms in human pancreatic cance...

journal_title：Anti-cancer drugs

authors： Chen H,Sun B,Pan S,Jiang H,Sun X

更新日期：2009-02-01 00:00:00

abstract：:The effect of association of hyperthermia with the anti-inflammatory drug rhein (RH), 4,5-dihydroxyanthraquinone-2-carboxylic acid, on the clonogenic activity of human glioma cells has been examined. RH inhibits neoplastic growth mainly through an ATP depletion, but thermal cell killing is not mediated by the drug-ind...

journal_title：Anti-cancer drugs

authors： Floridi A,Gentile PF,Bruno T,Delpino A,Iacobini C,Benassi M

更新日期：1992-08-01 00:00:00

abstract：:Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dihydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as potential candidates for gene-directed enzyme prodrug therapy. All the phthalimides are poor subst...

journal_title：Anti-cancer drugs

authors： Mehta LK,Hobbs S,Chen S,Knox RJ,Parrick J

更新日期：1999-09-01 00:00:00